心脉通胶囊联合瑞舒伐他汀治疗高脂血症的临床研究  

Clinical study on Xinmaitong Capsules combined with rosuvastatin in treatment of hyperlipidemia

作　　者：刘欣[1] 米晶晶 孙小春 LIU Xin;MI Jingjing;SUN Xiaochun(Department of Internal Medicine-Cardiovascular,Yulin Hospital,the First Affiliated Hospital of Xi’an Jiaotong University,Yulin 719000,China;Department of Pharmacy,Yulin Hospital,the First Affiliated Hospital of Xi’an Jiaotong University,Yulin 719000,China)

机构地区：[1]西安交通大学第一附属医院榆林医院心血管内科,陕西榆林719000 [2]西安交通大学第一附属医院榆林医院药剂科,陕西榆林719000

出　　处：《现代药物与临床》2024年第7期1792-1796,共5页Drugs & Clinic

基　　金：陕西省科技计划项目(2020SF-318)。

摘　　要：目的 探讨心脉通胶囊联合瑞舒伐他汀对高脂血症的治疗效果。方法 选取2021年3月—2023年9月在西安交通大学第一附属医院榆林医院诊治的高脂血症患者84例,随机分为对照组(42例)和治疗组(42例)。对照组口服瑞舒伐他汀钙片,5 mg/次,1次/d。治疗组在对照组基础上口服心脉通胶囊,4粒/次,3次/d。两组均治疗8周。观察两组患者临床疗效,比较治疗前后两组患者总胆固醇、三酰甘油、非高密度脂蛋白胆固醇(non-HDL-C)、低密度脂蛋白胆固醇(LDL-C)、内皮素-1、降钙素基因相关肽(CGRP)、超敏C反应蛋白(hs-CRP)和单核细胞趋化蛋白-1(MCP-1)水平。结果 治疗后,治疗组临床总有效率为95.24%,比对照组的80.95%明显升高(P<0.05)。治疗后,两组总胆固醇、三酰甘油、non-HDL-C、LDL-C、内皮素-1、hs-CRP和MCP-1水平均明显降低,而CGRP水平均明显升高(P<0.05),且与对照组比较,治疗组各项指标改善更加明显(P<0.05)。结论 在瑞舒伐他汀的基础上联合心脉通胶囊治疗高脂血症能有效提升降脂效果,可获得较为满意的疗效,并能发挥保护血管内皮功能的作用,改善患者的微炎症状态。Objective To explore the therapeutic effect of Xinmaitong Capsules combined with rosuvastatin in treatment of hyperlipidemia. Methods Patients (84 cases) with hyperlipidemia in Yulin Hospital, the First Affiliated Hospital of Xi’an Jiaotong University from March 2021 to September 2023 were randomly divided into control (42 cases) and treatment (42 cases) group. Patients in the control group were po administered with Rosuvastatin Calcium Tablets, 5 mg/time, once daily. Patients in the treatment group were po administered with Xinmaitong Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical evaluations were evaluated, the levels of total cholesterol, triglyceride, non-HDL-C, LDL-C, endothelin-1, CGRP, hs-CRP and MCP-1 in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 95.24%, which was significantly higher than that of the control group (80.95%, P < 0.05). After treatment, the levels of total cholesterol, triglyceride, non-HDL-C, LDL-C, endothelin-1, hs-CRP and MCP-1 were significantly decreased, while the level of CGRP was significantly increased in two groups (P < 0.05). Compared with the control group, the indexes in the treatment group were improved more significantly (P < 0.05). Conclusion The combination of rosuvastatin and Xinmaitong Capsules in treatment of hyperlipidemia can effectively improve the lipid-lowering effect, achieve satisfactory therapeutic effects, and play a role in protecting vascular endothelial function, improving the patient's micro inflammatory state.

关 键 词：心脉通胶囊 瑞舒伐他汀片 高脂血症 非高密度脂蛋白胆固醇 内皮素-1 降钙素基因相关肽 单核细胞趋化蛋白-1 

分 类 号：R973[医药卫生—药品]